Design, synthesis, and biological activity of novel tetrahydropyrazolopyridone derivatives as FXa inhibitors with potent anticoagulant activity

Publication date: 15 May 2017
Source:Bioorganic & Medicinal Chemistry, Volume 25, Issue 10
Author(s): Xiaoqing Sun, Zexin Hong, Moyi Liu, Su Guo, Di Yang, Yong Wang, Tian Lan, Linyu Gao, Hongxia Qi, Ping Gong, Yajing Liu
A series of novel tetrahydropyrazolopyridone derivatives containing 1,3,4-triazole, triazolylmethyl, and partially saturated heterocyclic moieties as P2 binding element was designed, synthesized, and evaluated in vitro for anticoagulant activity in human and rabbit plasma. All compounds showed moderate to significant potency, and compounds 15b, 15c, 20b, 20c, and 22b were further examined for their inhibitory activity against human FXa in vitro. While compounds 15c and 22b were tested for rat venous thrombosis in vivo. The most promising compound 15c, with an IC50 (FXa) value of 0.14μM and 98% inhibition rate, warranted further investigation as an FXa inhibitor.

Graphical abstract

http://ift.tt/2nL1Fy9